On March 17, 2016 Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016 in New Orleans (Press release, Celldex Therapeutics, MAR 17, 2016, View Source [SID:1234509616]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.
The following Celldex-sponsored abstracts have been selected for poster presentations at AACR (Free AACR Whitepaper):
Title: Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
Date/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 13
Abstract: CT023
Title: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma
Date/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 27
Abstract: 5032
Title: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues
Date/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 21
Abstract: 1373
Title: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy
Date/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 22
Abstract: 4866
The following investigator-sponsored abstracts have been selected for poster presentations at AACR (Free AACR Whitepaper):
Title: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapy
Date/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 10
Abstract: LB-081
Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer
Date/Time: Tuesday, April 19, 1:00 p.m. – 5:00 p.m. CDT
Location: Section 33
Abstract: 4209
Title: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma
Date/Time: Sunday, April 17, 1:00 p.m. – 5:00 p.m. CDT
Location: Section 16
Abstract: 296